Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Tisagenlecleucel Inj (IV)(DLBCL) (CDM 52594413) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved July 4, 2026 , from http://ppman.hank.ai/transparency/procedure/52594413/by-state?code_type=CDM
“Tisagenlecleucel Inj (IV)(DLBCL) (CDM 52594413) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/52594413/by-state?code_type=CDM. Accessed
July 4, 2026 .
“Tisagenlecleucel Inj (IV)(DLBCL) (CDM 52594413) by State,” HANK Price Transparency ,
accessed July 4, 2026 ,
http://ppman.hank.ai/transparency/procedure/52594413/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
52594413 — Tisagenlecleucel Inj (iv)(dlbcl)
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$549,309
National median
$455,142 – $667,019
IQR (p25 – p75)
11
hospitals filing
1
states
Walking in without insurance?
Cash / self-pay price
Cash median
$222,784
vs. negotiated
-59.4%
Hospitals reporting
11
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 52594413 (CDM), with interquartile range
State Median p25 p75
IN $549,309 $455,142 $667,019